Anemia and anti-tuberculosis treatment outcome in persons with pulmonary tuberculosis: A multi-center prospective cohort study

J Infect Public Health. 2023 Jun;16(6):974-980. doi: 10.1016/j.jiph.2023.04.009. Epub 2023 Apr 18.

Abstract

Background: Tuberculosis (TB) remains a major plague of humanity. People with TB (PWTB) are commonly anemic. Here, we assessed whether the severity of anemia in PWTB prior to anti-TB treatment (ATT) was a risk factor for an unfavorable outcome.

Methods: Patients ≥ 18 years old with culture-confirmed drug-susceptible pulmonary TB enrolled between 2015 and 2019 in a multi-center Brazilian cohort were followed for up to 24 months and classified according to anemia severity (mild, moderate, and severe), based on hemoglobin levels. A multinomial logistic regression model was employed to assess whether anemia was associated with unfavorable outcome (death, failure, loss to follow-up, regimen modification or relapse), compared to treatment success (cure or treatment completion).

Results: Among 786 participants who met inclusion criteria, 441 (56 %) were anemic at baseline. Patients with moderate/severe anemia were more HIV-seropositive, as well as more symptomatic and had higher frequencies of unfavorable outcomes compared to the other groups. Moderate/severe anemia (adjusted OR [aOR]: 7.80, 95 %CI:1.34-45.4, p = 0.022) was associated with death independent of sex, age, BMI, HIV and glycemic status.

Conclusion: Moderate/severe anemia prior to ATT was a significant risk factor for death. Such patients should be closely monitored given the high risk of unfavorable ATT outcomes.

Keywords: Anemia; Death; Hemoglobin; Tuberculosis; Tuberculosis treatment outcome.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Anemia* / complications
  • Anemia* / drug therapy
  • Anemia* / epidemiology
  • Antitubercular Agents / therapeutic use
  • HIV Infections* / complications
  • Humans
  • Prospective Studies
  • Treatment Outcome
  • Tuberculosis* / drug therapy
  • Tuberculosis, Pulmonary* / complications
  • Tuberculosis, Pulmonary* / drug therapy
  • Tuberculosis, Pulmonary* / epidemiology

Substances

  • Antitubercular Agents